<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340625</url>
  </required_header>
  <id_info>
    <org_study_id>R06-1188</org_study_id>
    <nct_id>NCT01340625</nct_id>
  </id_info>
  <brief_title>Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions</brief_title>
  <official_title>A Relative Bioavailability Study of 0.4 mg/35 Mcg Norethindrone and Ethinyl Estradiol Chewable Tablets Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared the relative bioavailability (rate and extent of absorption) of 0.4 mg/35
      mcg Norethindrone and Ethinyl Estradiol Chewable Tablets by Teva Pharmaceuticals, USA with
      that of 0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets manufactured by Warner Chilcott Company,
      Inc., following a single oral dose (2 * 0.4 mg/35 mcg chewable tablets) in healthy female
      adult volunteers administered under fasting conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Norethindrone</measure>
    <time_frame>Blood samples collected over a 60 hour period.</time_frame>
    <description>Bioequivalence based on Norethindrone Cmax (maximum observed concentration of drug substance in plasma).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Norethindrone</measure>
    <time_frame>Blood samples collected over a 60 hour period.</time_frame>
    <description>Bioequivalence based on Norethindrone AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of Norethindrone</measure>
    <time_frame>Blood samples collected over a 60 hour period.</time_frame>
    <description>Bioequivalence based on Norethindrone AUC0-inf (area under the concentration-time curve from time zero to infinity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Ethinyl Estradiol</measure>
    <time_frame>Blood samples collected over a 60 hour period.</time_frame>
    <description>Bioequivalence based on Ethinyl Estradiol Cmax (maximum observed concentration of drug substance in plasma).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Ethinyl Estradiol</measure>
    <time_frame>Blood samples collected over a 60 hour period.</time_frame>
    <description>Bioequivalence based on Ethinyl Estradiol AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of Ethinyl Estradiol</measure>
    <time_frame>Blood samples collected over a 60 hour period.</time_frame>
    <description>Bioequivalence based on Ethinyl Estradiol AUC0-inf (area under the concentration-time curve from time zero to infinity).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Investigational Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Norethindrone/Ethinyl Estradiol 0.4 mg/35 mcg Chewable Tablets (Teva)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Listed Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ovcon® 35 Fe 0.4 mg/35 mcg Chewable Tablets (Warner Chilcott)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norethindrone/Ethinyl Estradiol</intervention_name>
    <description>0.4 mg/35 mcg Chewable Tablets</description>
    <arm_group_label>Investigational Test Product</arm_group_label>
    <other_name>Zeosa®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ovcon® 35 Fe</intervention_name>
    <description>0.4 mg/35 mcg Chewable Tablets</description>
    <arm_group_label>Reference Listed Drug</arm_group_label>
    <other_name>Femcon® Fe</other_name>
    <other_name>Norethindrone/Ethinyl Estradiol (generic name)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Volunteers who have been informed of the nature of the study and agree to read,
             review, and sign the informed consent document prior to Period I dosing.

          -  Volunteers who have completed the screening process within 28 days prior to Period I
             dosing.

          -  Volunteers who are healthy adult women 18-35 years of age, inclusive, at the time of
             dosing.

          -  Volunteers who have a body mass index (BMI) between 19-30 kg/m2, inclusive, and weight
             at least 110 lbs.

          -  Volunteers who are healthy as documented by the medical history, physical examination,
             vital sign assessments, 12-lead electrocardiogram, clinical laboratory assessments,
             and by general observations. The physical examination will also include a
             gynecological exam. If the subject has completed an acceptable Papanicolaou smear and
             gynecological exam in the previous 12 months and documentation of acceptable results
             are provided, both will be deferred. Any abnormalities/deviations from the normal
             range that might be considered clinically relevant by the study physician and
             investigator will be evaluated for individual cases, documented in study files, and
             agreed upon by both the study physician and investigator prior to enrolling the
             volunteer in this study and for continued enrollment.

          -  Volunteers must practice an acceptable non-hormonal birth control method as judged by
             the investigator(s) at least 14 days prior to Period I dosing, throughout the study,
             and until 14 days after second period dosing.

        Exclusion Criteria:

          -  Volunteers who report receiving any investigational drug within 30 days prior to
             Period I dosing.

          -  Volunteers who report taking any oral contraceptives including estrogen and progestin
             combined pills and progestin only pills or patch within 28 days prior to Period I
             dosing, using injectable contraceptives within 6 months of first period dosing.

          -  Volunteers who have ever had progestational hormone implants.

          -  Volunteers who report any presence or history of a clinically significant disorder
             involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic,
             hematologic, endocrine, or neurologic systems or psychiatric disease as determined by
             the clinical investigator(s).

          -  Volunteers who report any presence or history of migraines or severe headaches.

          -  Volunteers who have systolic blood pressure lower than 90 or over 140 mmHg, diastolic
             blood pressure lower than 45 or over 90 mmHg will be excluded from the study.

          -  Volunteers who have a history of thrombotic disorders or have ever had cerebrovascular
             accident or transient ischemic attacks.

          -  Volunteers with a history of breast cancer or undiagnosed breast nodules, active
             malignancies or undiagnosed vaginal bleeding.

          -  Volunteers having other conditions that may be aggravated by fluid retention (as
             determined by principal investigator).

          -  Volunteers who have a history of jaundice with previous use of oral contraceptives or
             any other kinds of hormonal contraceptives.

          -  Volunteers whose clinical laboratory test values fall outside the accepted reference
             range and when confirmed on re-examination is deemed to be clinically significant.

          -  Volunteers who demonstrate a reactive screen for hepatitis B surface antigen,
             hepatitis C antibody, or HIV antibody.

          -  Volunteers who report a history of allergic response(s) to norethindrone/ethinyl
             estradiol or progestin/estrogens or related drugs.

          -  Volunteers who report the use of any systemic prescription medication in the 14 days
             prior to Period I dosing (with the exception of hormonal contraceptives).

          -  Volunteers with a history of clinically significant allergies including drug
             allergies.

          -  Volunteers who report a clinically significant illness during the 4 weeks prior to
             Period I dosing (as determined by the clinical investigators).

          -  Volunteers who report a history of drug or alcohol addiction or abuse within the past
             year.

          -  Volunteers who demonstrate a positive drug abuse screen for this study prior to Period
             I dose administration.

          -  Volunteers who currently use or have used tobacco products within 30 days prior to
             Period I dosing.

          -  Volunteers who report donating greater that 150 mL of blood within 30 days prior to
             Period I dosing. All subjects will be advised not to donate blood for 4 weeks after
             completing the study.

          -  Volunteers who report donating plasma within 30 days prior to Period I dosing. All
             subjects will be advised not to donate plasma for 4 weeks after completing the study.

          -  Volunteers who demonstrate a positive pregnancy screen.

          -  Volunteers who are currently pregnant of breastfeeding.

          -  Volunteers who are using or have used within the 3 months preceding Period I dosing
             any vaginally administered estrogen or progestin-containing products.

          -  Any volunteer who engages in unprotected sexual intercourse during the time interval
             starting 14 days prior to first period dosing and until 14 days after the Period II
             dosing.

          -  Volunteers who have had a hysterectomy or oophorectomy (unilateral or bilateral).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PRACS Institute, Ltd.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2011</study_first_posted>
  <results_first_submitted>April 27, 2011</results_first_submitted>
  <results_first_submitted_qc>April 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 25, 2011</results_first_posted>
  <last_update_submitted>April 27, 2011</last_update_submitted>
  <last_update_submitted_qc>April 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2011</last_update_posted>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
    <mesh_term>Norinyl</mesh_term>
    <mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Norethindrone/Ethinyl Estradiol (Test) First</title>
          <description>0.4 mg/35 mcg Norethindrone/Ethinyl Estradiol Chewable Tablets test product dosed in first period followed by 0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets reference product dosed in the second period.</description>
        </group>
        <group group_id="P2">
          <title>Ovcon® 35 Fe (Reference) First</title>
          <description>0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets reference product dosed in first period followed by 0.4 mg/35 mcg Norethindrone/Ethinyl Estradiol Chewable Tablets test product dosed in the second period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period of 28 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Norethindrone/Ethinyl Estradiol (Test) First</title>
          <description>0.4 mg/35 mcg Norethindrone/Ethinyl Estradiol Chewable Tablets test product dosed in first period followed by 0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets reference product dosed in the second period.</description>
        </group>
        <group group_id="B2">
          <title>Ovcon® 35 Fe (Reference) First</title>
          <description>0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets reference product dosed in first period followed by 0.4 mg/35 mcg Norethindrone/Ethinyl Estradiol Chewable Tablets test product dosed in the second period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Norethindrone</title>
        <description>Bioequivalence based on Norethindrone Cmax (maximum observed concentration of drug substance in plasma).</description>
        <time_frame>Blood samples collected over a 60 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Norethindrone/Ethinyl Estradiol (Test)</title>
            <description>0.4 mg/35 mcg Norethindrone/Ethinyl Estradiol Chewable Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Ovcon® 35 Fe (Reference)</title>
            <description>0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Norethindrone</title>
          <description>Bioequivalence based on Norethindrone Cmax (maximum observed concentration of drug substance in plasma).</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.94" spread="5.22"/>
                    <measurement group_id="O2" value="10.00" spread="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>107.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.91</ci_lower_limit>
            <ci_upper_limit>115.24</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Norethindrone</title>
        <description>Bioequivalence based on Norethindrone AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).</description>
        <time_frame>Blood samples collected over a 60 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Norethindrone/Ethinyl Estradiol (Test)</title>
            <description>0.4 mg/35 mcg Norethindrone/Ethinyl Estradiol Chewable Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Ovcon® 35 Fe (Reference)</title>
            <description>0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Norethindrone</title>
          <description>Bioequivalence based on Norethindrone AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.83" spread="30.50"/>
                    <measurement group_id="O2" value="40.73" spread="22.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>104.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.74</ci_lower_limit>
            <ci_upper_limit>111.88</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf of Norethindrone</title>
        <description>Bioequivalence based on Norethindrone AUC0-inf (area under the concentration-time curve from time zero to infinity).</description>
        <time_frame>Blood samples collected over a 60 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Norethindrone/Ethinyl Estradiol (Test)</title>
            <description>0.4 mg/35 mcg Norethindrone/Ethinyl Estradiol Chewable Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Ovcon® 35 Fe (Reference)</title>
            <description>0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of Norethindrone</title>
          <description>Bioequivalence based on Norethindrone AUC0-inf (area under the concentration-time curve from time zero to infinity).</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.67" spread="34.36"/>
                    <measurement group_id="O2" value="45.43" spread="27.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>101.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.73</ci_lower_limit>
            <ci_upper_limit>108.62</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Ethinyl Estradiol</title>
        <description>Bioequivalence based on Ethinyl Estradiol Cmax (maximum observed concentration of drug substance in plasma).</description>
        <time_frame>Blood samples collected over a 60 hour period.</time_frame>
        <population>34 out of 36 subjects completed the study. Subjects 13 &amp; 35 were excluded from the statistical analysis for Ethinyl Estradiol due to pre-dose concentrations greater than 5% of Cmax; therefore analysis included 32 data sets.</population>
        <group_list>
          <group group_id="O1">
            <title>Norethindrone/Ethinyl Estradiol (Test)</title>
            <description>0.4 mg/35 mcg Norethindrone/Ethinyl Estradiol Chewable Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Ovcon® 35 Fe (Reference)</title>
            <description>0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Ethinyl Estradiol</title>
          <description>Bioequivalence based on Ethinyl Estradiol Cmax (maximum observed concentration of drug substance in plasma).</description>
          <population>34 out of 36 subjects completed the study. Subjects 13 &amp; 35 were excluded from the statistical analysis for Ethinyl Estradiol due to pre-dose concentrations greater than 5% of Cmax; therefore analysis included 32 data sets.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230.56" spread="74.02"/>
                    <measurement group_id="O2" value="237.00" spread="62.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>96.24</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.04</ci_lower_limit>
            <ci_upper_limit>102.86</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Ethinyl Estradiol</title>
        <description>Bioequivalence based on Ethinyl Estradiol AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).</description>
        <time_frame>Blood samples collected over a 60 hour period.</time_frame>
        <population>34 out of 36 subjects completed the study. Subjects 13 &amp; 35 were excluded from the statistical analysis for Ethinyl Estradiol due to pre-dose concentrations greater than 5% of Cmax; therefore analysis included 32 data sets.</population>
        <group_list>
          <group group_id="O1">
            <title>Norethindrone/Ethinyl Estradiol (Test)</title>
            <description>0.4 mg/35 mcg Norethindrone/Ethinyl Estradiol Chewable Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Ovcon® 35 Fe (Reference)</title>
            <description>0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Ethinyl Estradiol</title>
          <description>Bioequivalence based on Ethinyl Estradiol AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).</description>
          <population>34 out of 36 subjects completed the study. Subjects 13 &amp; 35 were excluded from the statistical analysis for Ethinyl Estradiol due to pre-dose concentrations greater than 5% of Cmax; therefore analysis included 32 data sets.</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1976.72" spread="518.96"/>
                    <measurement group_id="O2" value="1989.82" spread="475.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>98.80</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.89</ci_lower_limit>
            <ci_upper_limit>103.97</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf of Ethinyl Estradiol</title>
        <description>Bioequivalence based on Ethinyl Estradiol AUC0-inf (area under the concentration-time curve from time zero to infinity).</description>
        <time_frame>Blood samples collected over a 60 hour period.</time_frame>
        <population>34 out of 36 subjects completed the study. Subjects 13 &amp; 35 were excluded from the statistical analysis for Ethinyl Estradiol due to pre-dose concentrations greater than 5% of Cmax; therefore analysis included 32 data sets.</population>
        <group_list>
          <group group_id="O1">
            <title>Norethindrone/Ethinyl Estradiol (Test)</title>
            <description>0.4 mg/35 mcg Norethindrone/Ethinyl Estradiol Chewable Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Ovcon® 35 Fe (Reference)</title>
            <description>0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of Ethinyl Estradiol</title>
          <description>Bioequivalence based on Ethinyl Estradiol AUC0-inf (area under the concentration-time curve from time zero to infinity).</description>
          <population>34 out of 36 subjects completed the study. Subjects 13 &amp; 35 were excluded from the statistical analysis for Ethinyl Estradiol due to pre-dose concentrations greater than 5% of Cmax; therefore analysis included 32 data sets.</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2129.43" spread="560.04"/>
                    <measurement group_id="O2" value="2131.84" spread="545.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>99.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.91</ci_lower_limit>
            <ci_upper_limit>104.50</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over the course of the study, which was approximately 6 weeks in duration.</time_frame>
      <desc>Volunteers were monitored throughout the study for any adverse experiences. AEs were collected through both solicited and unsolicited methods. The volunteers were encouraged to report signs, symptoms, and any changes in health to the clinic staff.</desc>
      <group_list>
        <group group_id="E1">
          <title>Norethindrone/Ethinyl Estradiol (Test) First</title>
          <description>0.4 mg/35 mcg Norethindrone/Ethinyl Estradiol Chewable Tablets test product dosed in first period followed by 0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets reference product dosed in the second period.</description>
        </group>
        <group group_id="E2">
          <title>Ovcon® 35 Fe (Reference) First</title>
          <description>0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets reference product dosed in first period followed by 0.4 mg/35 mcg Norethindrone/Ethinyl Estradiol Chewable Tablets test product dosed in the second period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Biopharmaceutics</name_or_title>
      <organization>Teva Pharmaceuticals, USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

